Nicotine stimulates the activity of mesolimbic dopamine neurons, which is believed to mediate the rewarding and addictive properties of tobacco use. Accumulating evidence suggests that the endocannabinoid system might play a major role in neuronal mechanisms underlying the rewarding properties of drugs of abuse, including nicotine. Here, we investigated the modulation of nicotine effects by the endocannabinoid system on dopamine neurons in the ventral tegmental area with electrophysiological techniques in vivo and in vitro. We discovered that pharmacological inhibition of fatty acid amide hydrolase (FAAH), the enzyme that catabolizes fatty acid ethanolamides, among which the endocannabinoid anandamide (AEA) is the best known, suppressed nicotine-induced excitation of dopamine cells. Importantly, this effect was mimicked by the administration of the FAAH substrates oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), but not methanandamide, the hydrolysis resistant analog of AEA. OEA and PEA are naturally occurring lipid signaling molecules structurally related to AEA, but devoid of affinity for cannabinoid receptors. They blocked the effects of nicotine by activation of the peroxisome proliferator-activated receptor-␣ (PPAR-␣), a nuclear receptor transcription factor involved in several aspects of lipid metabolism and energy balance. Activation of PPAR-␣ triggered a nongenomic stimulation of tyrosine kinases, which might lead to phosphorylation and negative regulation of neuronal nicotinic acetylcholine receptors. These data indicate for the first time that the anorexic lipids OEA and PEA possess neuromodulatory properties as endogenous ligands of PPAR-␣ in the brain and provide a potential new target for the treatment of nicotine addiction.
Introduction
Nicotine is the main active component in tobacco smoke, which initiates and sustains tobacco addiction. Hence, nicotine induces drug-seeking behavior in animals and many additional effects commonly seen with addictive drugs (Stolerman and Shoaib, 1991) . Among these effects, stimulation of mesolimbic dopamine (DA) transmission is considered to be one of the hallmarks to define the addicting potential of nicotine, being one of the common features of all abused drugs (Di Chiara and Imperato, 1988; Wise, 2004) . By acting at neuronal nicotinic acetylcholine receptors (nAChRs), nicotine activates ventral tegmental area (VTA) DA neurons (Mereu et al., 1987; Pidoplichko et al., 1997) and induces DA release in the nucleus accumbens (Di Chiara and Imperato, 1988) .
Among medications aimed at achieving smoking cessation, antagonists at the cannabinoid type-1 (CB 1 ) receptors show promise, based on preclinical data indicating that these compounds, such as rimonabant (SR141716A) or AM251, reduce nicotine self-administration or conditioned place preference (CPP) (Cohen et al., 2002; Le Foll and Goldberg, 2004; Forget et al., 2005; Shoaib, 2008) , nicotine-induced DA release in the nucleus accumbens (Cohen et al., 2002; Cheer et al., 2007) , or smoking cessation in humans (Cahill and Ussher, 2007) . These data strongly point to a facilitatory effect of the endocannabinoid system in the motivational and DA-releasing properties of nicotine. Indeed, endogenous cannabinoids, such as arachidonoylethanolamide (anandamide, AEA) and 2-arachidonoylglycerol, and CB 1 receptors are involved in the neuronal mechanisms underlying the rewarding effects of most drugs of abuse, including nicotine (Castañé et The present study was designed to investigate modulation of nicotine effects by the endocannabinoid system, and to clarify the role of DA neurons in the mediation of the antiaddicting properties of CB 1 antagonists. To this aim, the electrophysiological responses of DA neurons to nicotine administration were studied following either blockade of CB 1 receptors or, conversely, enhancement of brain endocannabinoid levels by inhibiting fatty acid amide hydrolase (FAAH) (Kathuria et al., 2003; Fegley et al., 2005) , the major hydrolyzing enzyme for AEA and other endogenous fatty acid ethanolamides (FAEs), such as the N-acylamines oleoylethanolamide (OEA) and palmitoylethanolamide (PEA). Unlike AEA, both OEA and PEA have no affinity for cannabinoid receptors, but bind to the peroxisome proliferator-activated receptor (PPAR), a family of nuclear receptor transcription factors (Fu et al., 2003; Lo Verme et al., 2005) . Three subtypes of PPARs (␣, ␤/␦ and ␥) play important roles in lipid metabolism, insulin sensitivity, glucose homeostasis and inflammation (Berger and Moller, 2002) . Through PPAR-␣, OEA and PEA are peripherally acting satiety signals that modulate feeding, body weight and lipid metabolism (Rodriguez de Fonseca et al., 2001; Fu et al., 2003) and have antinociceptive effects in visceral and inflammatory pain models (Lo Verme et al., 2005; D'Agostino et al., 2007; Suardiaz et al., 2007) .
We discovered that, contrary to our expectations, enhancement of brain FAE levels, rather than blockade of CB 1 receptors, inhibited the responses of DA neurons to nicotine. More importantly, the noncannabinoid FAEs OEA and PEA play a novel and unsuspected role, as PPAR-␣ agonists, in the negative regulation of neuronal responses to nicotine.
Materials and Methods
Electrophysiology: single unit recordings. We performed the experiments in strict accordance with the Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research (National Research Council 2004) and EEC Council Directive of 24 November 1986 (86/ 609) . We made all efforts to minimize pain and suffering and to reduce the number of animals used.
Male Sprague Dawley rats (250 -350 g) (Harlan) were housed in groups of three to six in standard conditions of temperature and humidity under a 12 h light/dark cycle (with lights on at 7:00 A.M.) with food and water available ad libitum.
Animals were anesthetized with urethane (1300 mg/kg, i.p.), their femoral vein was cannulated for intravenous administration of pharmacological agents, and they were placed in the stereotaxic apparatus (Kopf) with their body temperature maintained at 37 Ϯ 1°C by a heating pad. Thereafter, the scalp was retracted and one burr hole was drilled above the VTA (Ϫ6.0 mm anteroposterior from bregma, 0.3-0.6 mm lateral from midline) for the placement of a recording electrode. For intracerebroventricular drug administration, a guide cannula (23 gauge stainless steel) was placed into the ventricle ipsilateral to the recording side (1.0 mm posterior, 1.4 mm lateral to bregma and 4.0 mm ventral to the cortical surface). Structures were localized according to the stereotaxic atlas of Paxinos and Watson (1997) . Intracerebroventricular injections were made through a prefilled inner cannula (30 gauge stainless steel tubing) connected to a 50 l Hamilton microsyringe and extending 1.0 mm below the tip of the guide into the ventricle. Infusion rate was set at 2.5 l/min by an electrically driven mini-pump.
Single unit activity of neurons located in the VTA (V 7.0 -8.0 mm from the cortical surface) was recorded extracellularly with glass micropipettes filled with 2% pontamine sky blue dissolved in 0.5 M sodium acetate (impedance 2-5 M⍀). Single unit activity was filtered (bandpass 500 -5000 Hz) and individual spikes were isolated by means of a window discriminator (Digitimer), displayed on a digital storage oscilloscope (TDS 3012, Tektronics) and digitally recorded. Experiments were sampled on line and off line with Spike2 software (Cambridge Electronic Design) by a computer connected to CED 1401 interface (Cambridge Electronic Design).
Single units were isolated and identified according to already published criteria Bunney, 1983, 1984; Ungless et al., 2004) . Since only one cell was recorded per rat, VTA DA neurons were selected when all criteria for identification were fulfilled: firing rate Ͻ10 Hz, duration of action potential Ͼ2.5 ms, inhibitory responses to hindpaw pinching. Bursts were defined as the occurrence of two spikes at an interspike interval Ͻ80 ms, and terminated when the interspike interval exceeded 160 ms (Grace and Bunney, 1983) .
At the end of each recording section, direct current (10 A for 15 min) was passed through the recording electrode to eject Pontamine sky blue, which allowed the identification of the recorded cells. Brains were removed and fixed in 8% formalin solution. The position of the electrodes was microscopically identified on serial sections (60 m) stained with cresyl violet.
Electrophysiology: patch-clamp recordings. The preparation of VTA slices was as described previously (Johnson and North, 1992) . Briefly, male Sprague Dawley rats (10 -28 d) were anesthetized with halothane in a vapor chamber and killed by decapitation. A block of tissue containing the midbrain was rapidly dissected and sliced in the horizontal plane (300 m) with a vibratome (Leica VT1000S) in ice-cold low-Ca 2ϩ solution containing (in mM): 126 NaCl, 1.6 KCl, 1.2 NaH 2 PO 4 , 1.2 MgCl 2 , 0.625 CaCl 2 , 18 NaHCO 3 , and 11 glucose. Slices were transferred to a holding chamber with artificial CSF (ACSF, 37°C) saturated with 95% O 2 and 5% CO 2 containing (in mM): 126 NaCl, 1.6 KCl, 1.2 NaH 2 PO 4 , 1.2 MgCl 2 , 2.4 CaCl 2 , 18 NaHCO 3 , and 11 glucose. Slices were allowed to recover for at least 1 h before being placed in the recording chamber and superfused with the ACSF (37°C) saturated with 95% O 2 and 5% CO 2 . Cells were visualized with an upright microscope with infrared illumination (Axioskop FS 2 plus, Zeiss), and whole-cell patch-clamp recordings were made by using an Axopatch 200B amplifier (Axon Instruments). Both voltage-and current-clamp experiments were made with electrodes filled with a solution containing the following (in mM): 117 KCl 144, 10 HEPES, BAPTA 3.45, CaCl 1, 2.5 Mg 2 ATP, and 0.25 Mg 2 GTP (pH 7.2-7.4, 275-285 mOsm). Experiments were begun only after series resistance had stabilized (typically 15-40 M⍀). Series and input resistance were monitored continuously on-line with a 5 mV depolarizing step (25 ms). Data were filtered at 2 kHz, digitized at 10 kHz, and collected on-line with acquisition software (pClamp 8.2, Axon Instruments). DA neurons from the posterior VTA were identified by the presence of a large I h current (Johnson and North, 1992) that was assayed immediately after break-in, using a series of incremental 10 mV hyperpolarizing steps from a holding potential of Ϫ70 mV. Each slice received only a single drug exposure.
Drugs. Nicotine ((Ϫ)-nicotine hydrogen tartrate) was purchased from Sigma. OEA, PEA, methanandamide (mAEA), AM281, AM251, capsazepine, WY14643, MK886, genistein, PP2 were purchased from Tocris. Rimonabant (SR141716A) was a generous gift of Sanofi-Aventis Recherche (Montpellier). Nicotine was diluted in saline (pH ϭ 7). For i.c.v. administration, OEA or mAEA were dissolved in 40% w/v 2-hydroxypropyl-␤-cyclodextrin. mAEA for i.v. injections was dissolved in 2% Tween 80 and 2% ethanol and then diluted in saline. Rimonabant was emulsified in 1% Tween 80, then diluted in saline solution and sonicated. URB597 and MK886 were dissolved in DMSO (100 g/l) and diluted to the final concentration in saline. All drugs for patch-clamp experiments were dissolved in DMSO as stock solutions and then dilute to the final volume in ACSF (final concentration Ͻ0.01%).
Statistical analysis. Drug-induced changes in firing rate and pattern were calculated by averaging the effects after drug administration (2 min or 30 s bins for in vivo and in vitro electrophysiology, respectively) and normalizing to the predrug baseline. All the numerical data are given as mean Ϯ SEM. Data were compared and analyzed by using two-way ANOVA for repeated measures (treatment ϫ time), or one-way ANOVA or Student's t test for repeated measures, when appropriate. Post hoc multiple comparisons were made using the Dunnett's test. Statistical analysis was performed by means of the NCSS program. The significance level was established at p Ͻ 0.05.
Results

Effects of rimonabant and URB597 on activation of VTA dopamine neurons by nicotine in vivo
We recorded the activity of VTA DA neurons in urethane anesthetized rats. Cells were recorded only when they fulfilled all established criteria for VTA DA neuron identification (see Materials and Methods). A typical DA neuron broad waveform is shown in Figure 1 A. Consistent with previous in vivo studies (Mereu et al., 1987; Erhardt et al., 2002) , nicotine (0.2 mg/kg, i.v.) enhanced firing rate of VTA DA neurons to 144.2 Ϯ 24.2% of baseline and burst firing to ϩ 10.6 Ϯ 3.8% (F (5,71) ϭ 4.06, n ϭ 23, p Ͻ 0.05; F (5,71) ϭ 2.89, n ϭ 23, p Ͻ 0.05, respectively, one-way ANOVA for repeated measure) (Fig. 1B-D) . As previously reported, nicotineinduced excitation was short lasting, being significant 2 and 4 min following administration (Dunnett's post hoc). Injections of all the different vehicles (either intraperitoneal, intravenous, or intracerebroventricular) that were used in all subsequent experiments neither significantly changed the discharge activity of DA neurons nor modulated the effect of the subsequent nicotine administration. Therefore, all control experiments with nicotine were pooled.
We first studied the effect of CB 1 receptor blockade on nicotine-induced excitation of DA neurons. Rimonabant (SR141716A, 0.5 mg/kg, i.v. 4 min before nicotine) did not modify the excitatory response of DA neurons to nicotine compared with vehicle (F (1,103) ϭ 1.10, n ϭ 11, p ϭ 0.3, two-way ANOVA for repeated measures) (Fig. 1B-D) . Next, we investigated the effect of enhancement of endogenous endocannabinoid tone. Rats were pretreated between 60 and 120 min (average 72.4 min) before electrophysiological recordings with URB597 (0.1 mg/kg, i.v.), an irreversible FAAH inhibitor. The interval between URB597 administration and recordings varied among experiments, nevertheless, this dose of URB597 is within the range of doses shown to enhance persistently (Ͼ6 h) brain AEA levels (Kathuria et al., 2003; Fegley et al., 2005) , with maximal effects 1-2 h following administration (Fegley et al., 2005) . URB597 did not change spontaneous baseline firing rate (3.7 Ϯ 0.26 Hz, n ϭ 48, in control animals; 3.9 Ϯ 0.14, n ϭ 14, in URBpretreated animals, p ϭ 0.36, Student's t test) or burst firing (22.6 Ϯ 3.64% of spikes in bursts, n ϭ 48, in control animals; 23.0 Ϯ 5.15%, n ϭ 14; in URBpretreated animals, p ϭ 0.96, Student's t test) of VTA DA neurons assessed before nicotine administration, but, unexpectedly, it completely prevented nicotine's effects on DA neuronal activity (74.1 Ϯ 6.2% and Ϫ16.8 Ϯ 4.1% of baseline, for firing rate and burst firing, respectively) ( Fig. 1 B, C,D) . Two-way ANOVA showed a highly significant effect of URB597 treatment on the effects of nicotine on firing rate (F (1,95) ϭ 4.95, n ϭ 6, p Ͻ 0.01) and burst firing (F (1,107) ϭ 7.98, n ϭ 6, p Ͻ 0.01). Hence, following URB597 pretreatment, nicotine transiently inhibited, rather than excited, firing rate and burst firing of DA neurons (F (3,23) ϭ 3.73, p Ͻ 0.001, n ϭ 6; F (3,23) ϭ 9.44, p Ͻ 0.01, one-way ANOVA for repeated measures) (Fig. 1B,C,D) .
Contribution of CB 1 receptors and PPAR-␣ to URB597
antagonism of nicotine effects in vivo URB597 has been shown to increase not only AEA, but also OEA and PEA levels (Kathuria et al., 2003) . We first investigated whether AEA mediates URB597's antagonism of nicotine effects by acting at CB 1 receptors. For this purpose, we administered the CB 1 antagonist rimonabant together with URB597. Rimonabant (0.5 mg/kg, i.v. 1 min before URB597) significantly reduced the ability of URB597 to block nicotine-induced stimulation of DA neuron discharge rate (123.7 Ϯ 11.5% of baseline), but not of burst firing (Ϫ18.4 Ϯ 8.0% of baseline) (F (1,23) ϭ 11.04, n ϭ 9, p Ͻ 0.01; F (1,23) ϭ 2.30, n ϭ 9, p ϭ 0.2, respectively, two-way ANOVA for repeated measures) ( Fig. 2 A, B) . The CB 1 receptor antagonist AM251 (1.0 mg/kg, i.v. 1 min before URB597, n ϭ 5) fully replicated the effects of rimonabant (Fig. 2 A, B ) (firing rate: F (1,61) ϭ 10.96, n ϭ 6, p Ͻ 0.01; burst firing: F (1,75) ϭ 0.00, n ϭ 6, p ϭ 0.9, two-way ANOVA for repeated measures). This dissociation between URB597 effects on nicotine-induced increases in firing rate and burst firing was further analyzed by assessing the contribution of the noncannabinoid FAEs (OEA and PEA), which are ligands at PPAR-␣ (Fu et al., 2003) . We asked whether the effect of URB597 could be antagonized by the synthetic selective PPAR-␣ antagonist MK886 (3 mg/kg, i.p.). MK886 significantly prevented URB597 from altering nicotine-induced stimulation of bursting (ϩ10.5 Ϯ 3.5% of baseline) (F (1,72) ϭ 4.90, n ϭ 13, p Ͻ 0.05, two-way ANOVA for repeated measures) (Fig. 2 B) , but not firing rate (F (1,75) ϭ 0.0, n ϭ 13, p ϭ 0.95, two-way ANOVA for repeated measures) (Fig. 2 A) . These results suggest that diverse FAEs may modulate nicotine effects on DA neurons through different mechanisms.
Oleoylethanolamide blocks nicotine effects in vivo via PPAR-␣
To determine the precise contribution of either CB 1 or PPAR-␣ receptors in the observed effects, we assessed whether mAEA, the metabolically stable analog of AEA, and OEA modulated the response to nicotine of VTA DA neurons. mAEA was administered intravenously at doses of 1 and 5 mg/kg (n ϭ 6 each group) (Fig.  3 A, B) , or i.c.v. at a dose of 5 g/5 l (n ϭ 6) ( Fig. 3B ) 4 min before nicotine administration. These doses, which exert CB 1 receptor-mediated behavioral effects in vivo (Solinas et al., 2006 (Solinas et al., , 2007 , did not affect either baseline firing rate or burst firing of DA neurons or modulate the excitatory response to nicotine administration, compared with vehicle (F (3,234) ϭ 0.68, n ϭ 6, p ϭ 0.57, two-way ANOVA for repeated measures). Due to the poor metabolic stability of OEA, we chose to administer it (20 g/5 l), or a corresponding volume of vehicle (40% w/v 2-hydroxypropyl-␤-cyclodextrin), into the lateral ventricle 4 min before nicotine. In contrast to mAEA, OEA completely prevented the activation of DA neurons induced by nicotine (92.7 Ϯ 13.5% of baseline at 2 min postnicotine) (Fig. 3C,D) , whereas vehicle injection was inactive (n ϭ 6, data not shown). Two-way ANOVA showed a significant effect of OEA treatment on nicotineinduced stimulation of firing rate and burst firing (F (1,99) ϭ 5.61, n ϭ 6, p Ͻ 0.05; F (1,107) ϭ 4.28, n ϭ 6, p Ͻ 0.05, respectively, two-way ANOVA for repeated measures). Neither OEA nor vehicle produced significant changes in the spontaneous firing rate or burst firing of DA neurons (Fig. 3C,D) . Next, MK886 pretreatment (3 mg/kg, i.p., 30 min before recordings) prevented the blockade by OEA of nicotine's excitatory effects (122.8 Ϯ 7.2% of baseline at 4 min postnicotine), when compared with OEA alone (F (1,55) ϭ 6.06, n ϭ 8, p Ͻ 0.05, two-way ANOVA for repeated measures) (Fig. 3C,D) , thus highlighting the role of PPAR-␣ in the effects of OEA.
Blockade of nicotine-induced excitation of dopamine neurons in vitro by noncannabinoid fatty acid ethanolamides
We next asked whether modulation of nicotine effects by PPAR-␣ could be studied in brain slices containing the mesencephalon by using whole-cell patch-clamp recordings. The effect of nicotine was studied on posterior VTA DA neurons. Figure 4 A (top) shows a typical action potential of a representative DA neuron, when recorded in the current-clamp mode, with its typical low threshold, broad action potential, and prominent afterhyperpolarization. The second derivative of this action potential originates the waveform (Fig. 4 A, bottom) that has been used for cell identification of DA neurons in many in vivo extracellular studies Bunney, 1983, 1984; Ungless et al., 2004) , and qualitatively corresponds to the typical action potential recorded in vivo and shown in Figure 1 A. DA neurons recorded under current-clamp mode displayed an average frequency of 1.8 Ϯ 0.1 Hz (n ϭ 102) and fired spontaneously in a clock-like, single-spike mode. Consistent with the literature (Pidoplichko et al., 1997) , DA neurons responded to bath-applied nicotine (1 M, 2 min) with a transient excitation of discharge rate (ϳ40%) (Fig. 4 B-D) . This excitation peaked (137 Ϯ 12.8% of baseline, n ϭ 6), and was statistically significant (F (6,41) ϭ 8.03, p Ͻ 0.0001, one-way ANOVA), during the first minute of application. Under voltageclamp mode (V holding ϭ Ϫ70 mV), nicotine caused a transient inward current of 40.3 Ϯ 5.6 pA (n ϭ 6) (Fig. 4 F) , due to rapid activation and desensitization of nAChRs (Pidoplichko et al., 1997) . We next examined the effects of the three different FAEs (i.e., mAEA, OEA and PEA) on nicotine induced excitation of VTA DA neurons. These drugs were applied for 5 min to assess whether they per se modulated spontaneous firing of DA neurons, and then coapplied with nicotine (1 M). mAEA was tested at two different concentrations, 30 nM and 1 M. The lower concentration of mAEA did not significantly affect spontaneous discharge rate of DA neurons or modulate nicotine-evoked excitation (the peak of nicotine with mAEA was 147.7 Ϯ 13.7% of baseline firing rate, p ϭ 0.58, t test, vs nicotine alone) (Fig. 4 E, G) .
Since this concentration of mAEA might have been too low, we next tested a concentration of 1 M, which itself significantly enhanced firing rate of DA neurons to 370.6 Ϯ 110% of baseline level (F (5,125) ϭ 21.74, n ϭ 6, p ϭ 0.0001, one-way ANOVA for repeated measures; data not shown). We asked whether mAEAinduced stimulation was due to activation of CB 1 and/or TRPV1 receptors. The CB 1 receptor antagonist AM281, at a concentration (500 nM) that fully reverses activation of CB 1 receptors by maximal concentrations of agonists (Melis et al., 2004) , had no effect on mAEA-induced stimulation of DA neuron firing rate (F (1,72) ϭ 0.67, n ϭ 5, p ϭ 0.4365, two-way ANOVA; data not shown). However, this stimulation was completely blocked by the TRPV1 receptor antagonist capsazepine (10 M, F (1,171) ϭ 8.13, n ϭ 5-6, p ϭ 0.019, two-way ANOVA; data not shown). This observation is consistent with other studies showing that TRPV1 agonists stimulate DA neuron activity by enhancing glutamatergic synaptic transmission onto DA neurons (Marinelli et al., 2005) . To isolate the agonistic activity of mAEA at CB 1 receptors, or possibly at PPAR-␣, and avoid TRPV1-induced excitation of DA cells that could mask or confound the effects of the subsequent application of nicotine, we applied nicotine in the presence of capsazepine. Under these circumstances, excitatory effects of nicotine were unmodified compared with controls (151.4 Ϯ 13.5% of baseline, t ϭ 0.77, n ϭ 6, p ϭ 0.4563, t test) (Fig. 4G) , suggesting that CB 1 receptor stimulation did not affect nicotineinduced excitation of DA neuron firing and that mAEA did not activate PPAR-␣ (see below).
Next, we tested two different noncannabinoid FAEs, OEA and PEA. Interestingly, OEA (0.3, 1 and 3 M) dosedependently prevented nicotine-induced excitation (97.44 Ϯ 5% and 92.01 Ϯ 7% of baseline at 1 and 3 M, respectively; 1 M: n ϭ 5, t ϭ 2.65, p ϭ 0.01; 3 M: n ϭ 7, t ϭ 3.22, p ϭ 0.04) (Fig. 4 H) , without affecting DA neuron spontaneous activity during preapplication (Fig. 4 E) . The effects of OEA were mimicked by PEA (10 M, 101.9 Ϯ 3% of baseline, n ϭ 6, t ϭ 2.66, p ϭ 0.01) (Fig. 4 E, G) . Consistently, under voltage-clamp mode (V holding ϭ Ϫ70 mV), the nicotine-induced inward current was completely abolished when nicotine was perfused in the presence of OEA (3 M, 5 min preapplication: Ϫ0.3 Ϯ 3.4 pA, n ϭ 6, t ϭ 7.13, p ϭ 0.0004, paired t test) (Fig.  4 F) , or PEA (10 M, 5 min preapplication: Ϫ0.6 Ϯ 7.5 pA, N ϭ 5, t ϭ 4.442, p ϭ 0.001, paired t test) (Fig. 4 F) . During preapplication, OEA and PEA did not induce inward or outward currents onto DA neurons (data not shown).
Based on these results, we expected that the PPAR-␣ antagonist MK886 would block the actions of OEA and PEA on nicotine-induced excitation. As predicted, when OEA or PEA were coapplied with MK886 (300 nM), nicotine's effects on firing rate of DA neurons were restored (155.8 Ϯ 16.6% and 163.8 Ϯ 11.3% of baseline in the presence of OEA and PEA, respectively; OEAϩMK886 vs OEA alone: F (2,323) ϭ 7.59, n ϭ 8, p ϭ 0.004, two-way ANOVA; PEAϩMK886 versus PEA alone: F (1,228) ϭ 4.84, n ϭ 8, p ϭ 0.04, two-way ANOVA) (Fig. 5 A, B,C) . MK886 when perfused either alone or in combination with OEA/PEA did not alter spontaneous firing rate of VTA DA neurons (Fig. 5C ). However, MK886 significantly enhanced nicotine-induced activation of DA neurons (207 Ϯ 27% of baseline, MK886ϩnicotine vs nicotine: t ϭ 2.167, n ϭ 7, p Ͻ 0.05, t test) (Fig. 5B) .
Next, we determined whether the synthetic PPAR-␣ agonist WY14643 would alter the effects of nicotine on DA cells. WY14643 (300 nM) was per se ineffective on DA neuronal firing rate, but fully prevented nicotine-induced excitation (83.7 Ϯ 14.7% of baseline, n ϭ 9, t ϭ 2.54, p ϭ 0.02) (Fig. 5 D, E) . The effect of WY14643 was also reversed by MK886 (167.7 Ϯ 22.7% of baseline; WY14643ϩMK886 vs WY14643 alone: F (1,228) ϭ 5.30, n ϭ 5, p Ͻ 0.05, two-way ANOVA) (Fig. 5D,E) , confirming the role of PPAR-␣ in the modulation of DA neuron responses to nicotine.
Mechanisms downstream of PPAR-␣ activation in the modulation of nicotine effects: involvement of tyrosine kinases
Although it is well established that PPAR-␣ regulates gene expression (Berger and Moller, 2002) , the effects of OEA, PEA and WY14643 observed in the present study were fairly rapid in onset, thus ruling out gene induction as a possible mechanism, and suggesting a more likely nongenomic (Gardner et al., 2005) mechanism occurring in such a short time scale. Among many diverse pathways, we chose to investigate the regulation of tyrosine kinases, because PPAR-␣ agonists have been shown to activate several tyrosine kinases, such as the Src family kinase (SFK) (Gardner et al., 2005) , which phosphorylates and negatively regulates ␣7 nAChRs (Charpantier et al., 2005) .
We hypothesized that phosphorylation of nAChRs could account for PPAR-␣ mediated inhibition of nicotine effects. To explore this possibility, we incubated slices with the general tyrosine kinase inhibitor genistein (10 M), which has indirect effects on nAChRs arising from the inhibition of intracellular phosphorylation pathways. Experiments were conducted under voltage-clamp mode on nicotine-induced inward currents, since genistein had aspecific channel blocker properties which led to a complete blockade of action potential generation (data not shown). Genistein was able to prevent OEA blockade of nicotine effects and restored nicotine-evoked inward currents (37.8 Ϯ 4.4 pA, n ϭ 6, t ϭ 6.79, p Ͻ 0.0001) (Fig. 6A,B) , demonstrating that inhibition of tyrosine kinases reverses the effect of PPAR-␣ activation.
To investigate which tyrosine kinase phosphorylates and negatively modulates nAChRs, we focused on SFKs, on the basis of previous reports highlighting the role of SFK in the regulation of ␣7 nAChRs (Charpantier et al., 2005) . We predicted that inhibition of SFK would reverse the effects of OEA. To test this hypothesis, slices were incubated (1 h) and continuously perfused with the SFK inhibitor PP2 (10 M). This treatment did not change electrophysiological features of recorded DA neurons (data not shown). However, PP2 failed to reverse OEA blockade of nicotine's effects on DA cells under both voltage-and current-clamp modes. Indeed, in the presence of PP2, OEA abolished nicotineinduced inward currents (Ϫ1.4 Ϯ 5.7, n ϭ 5, t ϭ 0.16, p Ͼ 0.5) (Fig. 6 A, B) as well as the nicotine-induced enhancement of firing rate (100.9 Ϯ 7.1% of baseline, F (1,108) ϭ 0.06, n ϭ 6, p ϭ 0.8, two-way ANOVA) (Fig. 6C,D) , suggesting that SFK is not involved in the negative modulation of nAChRs by PPAR-␣ agonists. 
Discussion
The present study revealed that naturally occurring noncannabinoid FAEs can modulate the responses of VTA DA neurons to nicotine via PPAR-␣, possibly by phosphorylation of nAChRs. This is the first evidence of an important functional role of this family of nuclear receptor transcription factors in the brain. It also highlights the role of FAEs, devoid of cannabinoid actions, in the regulation of neuronal functions.
Centrally mediated effects of the noncannabinoid FAEs have been poorly characterized, although OEA and PEA might constitute an independent endocannabinoid-like system. This view is supported by the findings that their synthesis and inactivation occurs independently of "classic" endocannabinoids, although in a similar on demand manner (Hansen et al., 1995; Stella and Piomelli, 2001; Mackie and Stella, 2006) . The molecular targets underlying their pharmacological effects have remained elusive until the discovery of their agonistic actions at PPAR-␣ (Fu et al., 2003) . These nuclear receptors are ubiquitously distributed in the CNS (Moreno et al., 2004) , but their roles in neuronal physiology, or in pathophysiological mechanisms of brain disorders, are largely unknown.
Indirect enhancement of brain FAEs levels obtained by blockade of their major hydrolyzing enzyme, FAAH, by URB597 (Kathuria et al., 2003) has been reported to produce antidepressant, anxiolytic and analgesic effects in rodents (Kathuria et al., 2003; Gobbi et al., 2005; Piomelli et al., 2006; Russo et al., 2007) . All of these effects are prevented by treatment with CB 1 receptor antagonists, and have been ascribed to increased AEA levels, thus suggesting that augmented levels of OEA and PEA do not contribute significantly. However, a PPAR-␣ antagonist was recently reported to block the peripheral analgesic effects of URB597, suggesting that analgesia may be mediated by FAEs binding at PPAR-␣ (Jhaveri et al., 2008) . In the present experiments, we discovered that inhibition of FAAH, rather than blockade of CB 1 receptors, suppresses nicotine-induced activation of DA neurons. The lack of effect by rimonabant was unexpected in light of recent reports that CB 1 antagonists decrease DA release evoked by nicotine in the nucleus accumbens (Cohen et al., 2002; Cheer et al., 2007) . One can argue, however, that the suppression by rimonabant of evoked DA release may be independent from the inhibition of firing activity of DA neurons in the VTA, and may be an effect primarily involving their terminal regions or local circuits within the nucleus accumbens. Hence, presynaptically located nAChRs potently regulate DA release in the striatum, including the nucleus accumbens (Zhou et al., 2001 ). The effect of URB597 was even more surprising, since it contradicts the notion that the endocannabinoid system exerts a facilitatory effect on nicotine reward and addiction. Consistent with the present results, recent findings indicate that URB597 prevents the development of nicotineinduced CPP, acquisition of nicotine selfadministration and nicotine-induced reinstatement in both CPP and selfadministration models of relapse (Scherma et al., 2008) .
Here, we found that the effects of URB597 were not entirely dependent on CB 1 receptor stimulation, since nicotineinduced increases in DA neuron bursting were not reversed by rimonabant or AM251, whereas increases in firing rate were. The PPAR-␣ antagonist MK886 reversed URB597's blockade of nicotineinduced bursting in DA neurons, suggesting that FAEs, other than AEA, play a role in antagonizing the effects of nicotine. More importantly, OEA, but not mAEA, blocked the effects of nicotine on DA neurons in vivo. These results were substantiated by the findings that both OEA and PEA, but not mAEA, completely prevented nicotine-induced excitation of DA neurons in vitro. Additionally, OEA and PEA actions via PPAR-␣ were confirmed by the antagonism exerted by MK886, and by the observation that the PPAR-␣ agonist WY14643 mimicked the actions of noncannabinoid FAEs. Although AEA has been reported to display binding affinity for PPAR-␣ (Sun et al., 2006 (Sun et al., , 2007 , our results are not consistent with those findings, since mAEA had no effects on nicotine-induced excitation of DA neurons, contrary to OEA and PEA. However, the studies of Sun et al. (2006 Sun et al. ( , 2007 were performed in HeLa cells transiently transfected with PPAR-␣, thus other investigations are necessary to confirm the binding properties of AEA at PPAR-␣ under more physiological conditions and, more importantly, in neurons. Remarkably, the analgesic properties of mAEA are fully preserved in PPAR-␣ knock-out mice, suggesting a PPAR-␣-independent mechanism of action, whereas those of OEA and PEA are abolished (LoVerme et al., 2006) .
Studies on recombinant or native nAChRs expressed in Xenopus oocytes or in mouse thalamic synaptosomes, respectively, have demonstrated that AEA (Oz et al., 2003; Spivak et al., 2007; Butt et al., 2008) or fatty acids (Butt et al., 2002; Barrantes, 2004) can modulate nAChR function as noncompetitive antagonists. Our results tend to exclude this possibility. In fact, they strongly support the notion that OEA and PEA effects are specifically mediated by PPAR-␣, since they are blocked by the selective synthetic antagonist and mimicked by the agonist. Additionally, we found that mAEA did not alter nicotine-induced DA neuron excitation, making its action as nAChR antagonist unlikely.
As mentioned above, rimonabant revealed a significant component mediated by CB 1 receptors in the effects of URB597. This piece of evidence is apparently difficult to reconcile with the results obtained with mAEA. Hence, mAEA does not significantly modulate nicotine's effects either in vivo or in vitro, arguing against an involvement of CB 1 receptors in the modulation of the excitatory actions of nicotine on VTA DA neurons. There are possible explanations for this discrepancy: first, the effects of URB597 are due to the combination of CB 1 -(by AEA) and PPAR-␣-(by OEA and PEA) mediated effects. CB 1 receptors and PPAR-␣ may share opposing or reinforcing intracellular pathways (including modulation of protein kinases) (for review, see Alexander and Kendall, 2007) . Second, URB597 enhances brain levels of endogenously released FAEs in a discrete and regionspecific manner, and may influence the release of other endocannabinoids as well, including 2-arachidonoylglycerol (Di Marzo and Maccarrone, 2008; Maccarrone et al., 2008) . Conversely, exogenously applied mAEA induces the activation of CB 1 receptors throughout the brain. The third possible explanation is a differential involvement of TRPV1 channels, which may be activated by AEA (following URB597 administration) or by mAEA itself. However, our results in vitro tend to exclude the possibility that TRPV1 receptors play a significant role in the modulation of nicotine effects, since their activation by mAEA, or blockade by the selective antagonist capsazepine did not change nicotineinduced excitation of DA neurons. We investigated also the mechanism by which PPAR-␣ may modulate the effects of nicotine. Due to the rapid onset of agonist actions, we hypothesized that this could be a nongenomic effect. Hence, PPARs exert pleiotropic effects on many different intracellular pathways, including protein kinases (Gardner et al., 2005) . It was recently shown that the functional properties of ␣7 nAChRs depend on the tyrosine phosphorylation status of the receptor, being the result of a balance between SFKs and tyrosine phosphatases (Charpantier et al., 2005) , which negatively or positively modulate nAChR-mediated currents, respectively. Additionally, phosphorylation/dephosphorylation of tyrosine residues in nAChRs controls the number of functional surface receptors (Cho et al., 2005) .
Interestingly, we found that the effects of the tyrosine kinase inhibitor genistein were consistent with the idea that PPAR-␣-mediated nAChR phosphorylation could account for the blockade of neuronal responses to nicotine, although at this stage we cannot identify the specific tyrosine kinase involved. A proposed mechanism is displayed in Figure 7 . A constitutive interaction between PPAR-␣ and tyrosine kinases is also possible, and may tonically control the ratio of phosphorylated/dephosphorylated nAChRs, as indicated by the enhanced effects of nicotine in the presence of the PPAR-␣ antagonist MK886. It cannot be excluded that OEA and PEA may be endogenous modulators of acetylcholine transmission, since stimulation of muscarinic receptors was shown to stimulate the biosynthesis of OEA and PEA (Stella and Piomelli, 2001) , suggesting the intriguing possibility of a reciprocal control between acetylcholine and FAEs.
This novel mechanism of regulation of nAChRs by PPAR-␣ may represent a new therapeutic avenue for the discovery of medications to support patients during nicotine abstinence. Our data demonstrate that the actions of OEA are not restricted to the periphery and suggest that modulation of neuronal responses to nicotine by OEA may represent an interesting extension of its peripheral anorexic properties. PPAR-␣ agonists, such as fibrates, are well established medications clinically used in the treatment of lipid metabolism disorders. Their central effects are considered negligible due to their poor ability to cross the blood brain barrier. However, changes in brain lipid metabolism and/or composition, or modifications of the levels of endogenous lipid signaling molecules may exert unsuspected actions on neurotransmitter functions, which might be exploited therapeutically. Figure 7 . Schematic diagram illustrating the proposed mechanism of PPAR-␣ activation, and modulation of responses of DA neurons to nicotine, by the noncannabinoid fatty acid ethanolamides OEA and PEA. Their action is mimicked by the synthetic PPAR-␣ agonist WY14643 and blocked by the PPAR-␣ antagonist MK886. URB597 enhances brain levels of OEA and PEA in vivo by inhibiting their major catabolizing enzyme, FAAH. It is proposed that activated PPAR-␣ stimulate the activity of tyrosine kinases (Tyr Kin) through a nongenomic mechanism. Tyrosine kinases, in turn, induce the phosphorylation (P) of nAChR, which reduces their responses to the agonists, or promotes rapid internalization. Genistein, a general tyrosine kinase inhibitor, blocks the effects of PPAR-␣ activation. 2, activation; Ќ, inhibition.
